Company: TVRD
Filing Date: 2025-01-27
Form Type: S-4/A
Source: 0001104659-25-006050
Chunk: 858

Company: Tvardi Therapeutics, Inc.
Filing Date: 2025-01-27
Form: S-4/A
Chunk 858
---
 of $0.5 million was converted into 500,000 shares of Series A Preferred Stock at a conversion price of $1.00 per share pursuant to the terms of grant agreement, dated as of March 2018. The following tables summarize the Company’s redeemable convertible preferred stock as of December 31, 2023 and 2022:

| ​                        
 ​                        
 ​                        
 ​                        | ​ 
 ​ 
 ​ | ​         
 ​         
 ​         
 Par Value |     ​ 
     ​ 
     ​ | ​ 
 ​ 
 ​ |               ​ 
               ​ 
 Preferred Stock 
      Authorized | ​ 
 ​ 
 ​ |               ​ 
 Preferred Stock 
      Issued and 
     Outstanding | ​ 
 ​ 
 ​ | ​        
 ​        
 Carrying 
 Value    |      ​ 
      ​ | ​ 
 ​ 
 ​ | ​           
 ​           
 Liquidation 
 Preference  |      ​ 
      ​ | ​ 
 ​ 
 ​ | ​             
 Common Stock  
 Issuable Upon 
 Conversion    |          ​ |
|:-------------------------|:--|:----------|------:|:--|----------------:|:--|----------------:|:--|:---------|-------:|:--|:------------|-------:|:--|:--------------|-----------:|
| Series A preferred stock | ​ | $         | 0.001 | ​ |       9,499,999 | ​ |       9,499,999 | ​ | $        |  9,327 | ​ | $           |  9,500 | ​ | ​             |  9,499,999 |
| Series B preferred stock | ​ | ​         | 0.001 | ​ |      20,223,541 | ​ |      20,055,539 | ​ | ​        | 76,176 | ​ | ​           | 76,402 | ​ | ​             | 20,055,539 |
| ​                        | ​ | ​         |     ​ | ​ |      29,723,540 | ​ |      29,555,538 | ​ | $        | 85,503 | ​ | $           | 85,902 | ​ | ​             | 29,555,538 |

F-105

8. Redeemable Convertible Preferred Stock (continued)

The key terms of Preferred Stock are as follows:

Dividends

The Company shall not declare, pay or set aside any dividends on shares or any other